SONO TEK CORP Form 10KSB May 27, 2004

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-KSB

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year ended: February 29, 2004

Commission File Number: 0-16035

SONO-TEK CORPORATION (Name of Small Business Issuer in its Charter)

NEW YORK 14-1568099

(State or other Jurisdiction of (IRS Employer Identification Number)

Incorporation or Organization)

2012 Route 9W, Milton, New York 12547 (Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (845) 795-2020

Securities Registered Pursuant to Section 12(b) of the Act: None

Securities Registered Pursuant to Section 12(g) of the Act: Common Stock, \$.01 par value (Title of Class)

Check whether the Issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. |X| Yes |\_| No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-B is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. |X|

The Issuer had revenues of \$3,501,594 for Fiscal Year ended February 29, 2004

As of May 21, 2004 the aggregate market value of the Registrant's Common Stock held by non-affiliates of the Registrant was approximately \$8,821,801 computed by reference to the average of the bid and asked prices of the Common Stock on said date, which average was \$1.00.

The Registrant had 10,982,901 shares of Common Stock outstanding as of May  $21,\ 2004$ .

#### ITEM 1 BUSINESS

Organization and Business.

Sono-Tek Corporation (the "Company" or "Sono-Tek") was incorporated in New York on March 21, 1975 for the purpose of engaging in the development, manufacture and sale of ultrasonic liquid atomizing nozzles. Ultrasonic nozzle systems atomize low to medium viscosity liquids by converting electrical energy into mechanical motion in the form of high frequency ultrasonic vibrations that break liquids into minute drops that can be applied to surfaces at low velocity.

The Company operates in one business segment, spraying systems. Since inception, the spraying systems business has had periods of sales growth and financial stability, but has had sales declines when the electronics industry has had downturns due to lower levels of printed circuit boards being made. To offset this, the Company has diversified its product offerings to provide coating systems to medical device manufacturers, to provide spray drying systems for nanotechnology applications, to provide components used in systems for the manufacture of solder paste, and to provide wide area industrial precision coating equipment.

#### Product Development

The Company has core technology and has developed the following products that have expanded its market opportunities:

- SonoFlux 2000F spray fluxer product designed for high volume operations with standard width lines requiring low maintenance using a variety of solder fluxes, including rosin flux. It is designed to be used by electronic circuit board manufacturers to apply solder flux to fixed width circuit boards. The major customers for the SonoFlux 2000F are original equipment manufacturers (OEMs) who produce their own electronic circuit boards.
- 2. SonoFlux XL spray fluxer product applies solder flux to electronic printed circuit boards that vary from two inches to up to 24 inches in width in a cost-effective and uniform manner. It is designed to be used by either OEMs or contract manufacturers of electronic circuit assemblies.
- 3. Accumist(TM) for stent coating A new turn-key, table-top fully contained system designed to apply expensive polymer and drug coatings to arterial stents with great precision in very thin layers. This system provides rotational and axial control of stent coating for excellent uniformity, low material wastage and is packaged in a glove box enclosure.

2

- 4. MicroMist nozzle system A high precision nozzle configuration which is available with a multi-axis computer-controlled positional system. Precise patterns of lines and dots can be achieved with minimal overspray. Used in electronic, medical and other industrial applications.
- 5. MediSonic Ultra-thin computer-controlled coating system utilizing licensed and patented technology. This system uses a process of liquid delivery through a Sono-Tek ultrasonic nozzle dispensed into a vacuum environment. It is designed to apply successive coats of

polymer-based chemicals to be used by medical device manufacturers to coat stents and other implantable devices.

- 6. WideTrack Wide area coating system uses one nozzle to cover up to 24 inches wide target areas and multiple nozzles to cover any width material. It uses a non-clogging ultrasonic atomizing nozzle to produce a low velocity, highly controllable spray. It is designed to be used by glass manufacturers or by any company that requires efficient web-coating or wide area spraying capability.
- 7. Molten Mist A new ultrasonic system for atomizing metals and other melts. Used in the manufacture of solder paste and features dual air/liquid cooling and a simple replaceable tip. It is designed to be used by high volume producers of solder paste.
- 8. SonoDry New spray drying nozzle for nanotechnology applications. It is incorporated into a laboratory sized spray dryer and marketed to research institutions and small producers of nanotechnology particles.

Management believes that the Company's long-term growth and stability is linked to the development and release of products that provide total solutions to customer needs across a wide spectrum of industries, while advancing the utility of the Company's core technology. The Company expended approximately 10.4% and 11.4% of its Fiscal Years 2004 and 2003 total revenues, respectively, on new engineering and product development.

#### Manufacturing

The Company purchases circuit board assemblies and sheet metal components from outside suppliers. These materials are available from a wide range of suppliers throughout the world. All raw materials used in the Company's products are readily available from many different domestic suppliers. The Company provides a limited warranty on all of its products covering parts and labor for a period of one year from the date of sale. The Company has a business and quality control system that meets the qualifications of ISO 9001/2000. The Company was ISO 9001 registered in September 1998 and has been recertified annually since then.

3

#### Patents

The Company's business is based in part on the technology covered by United States patents held by the Company. Patent applications, based on the United States applications, covering fundamental aspects of the ultrasonic technology developed by the Company, have been issued in several foreign jurisdictions. The Company's effective patents will expire in December 2007. The Company's patent on its central bolt design, used in current product offerings, expires in July 2004. However, the Company also relies on unpatented know-how in the production of its nozzle systems. The Company has executed non-disclosure, non-compete agreements with all of its employees to safeguard its intellectual property. The Company executes reciprocal non-disclosure agreements with its key customers to safeguard any jointly developed know-how.

The Company has a patent pending on a process for coating stents, substrates or objects with thin organic films and products, the technology used in its Thinsonic and Medisonic CVD (chemical vapor deposition) products.

The Company has started a patent application for a new nozzle design in fiscal year 2004 for its Molten Mist nozzle system and applications.

Marketing and Distribution

The Company markets and distributes its products through independent sales representatives or sales representative companies, OEMs and through an in-house direct sales force. Many of the Company's sales leads are generated from the Company's Internet web site and from attendance at major industry trade shows.

Competition

The Company operates in a highly competitive environment for its electronics manufacturing equipment. The Company maintains its competitive position by providing highly effective solutions that meet its customers' requirements.

Significant Customers

One customer accounted for 15% of the Company's sales for Fiscal Year ended February 29, 2004.

Foreign and Export Sales

During Fiscal Years 2004 and 2003, sales to foreign customers accounted for approximately \$855,000 and \$656,000, or 25% and 21% respectively, of total revenues.

4

#### Employees

As of May 21, 2004, the Company had 26 full-time employees and three part-time employees. The Company believes that its relationship with its employees is good.

#### ITEM 2 PROPERTIES

The Company's offices, product development, manufacturing and assembly facilities are located in a building in Milton, New York, consisting of 13,000 square feet pursuant to a lease that expires on November 30, 2005. The Company's current manufacturing areas consist of (i) a machine shop, (ii) a nozzle assembly/test area, (iii) an electronics assembly area, and (iv) a receiving and shipping area.

ITEM 3 LEGAL PROCEEDINGS

None.

ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

PART II

ITEM 5 MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDERS MATTERS

(a) The Company's Common Stock trades in the over-the-counter market on the OTC Bulletin Board. The following table sets forth the range of high and

low closing bid quotations for the Company's Common Stock for the periods indicated.

FISCAL YEAR ENDED	FEBRUA	RY 29,	FEBRUARY 28,			
	200	4	2003			
	HIGH	LOW	HIGH	LOW		
First Quarter	\$0.30	\$0.10	\$0.50	\$0.32		
Second Quarter	0.30	0.16	0.40	0.20		
Third Quarter	0.70	0.19	0.25	0.10		
Fourth Quarter	0.89	0.40	0.20	0.12		

The above quotations are believed to represent inter-dealer quotations without retail markups, markdowns or commissions and may not represent actual transactions. The Company believes that, although limited or sporadic quotations exist, there is no established public trading market for the Company's Common Stock.

5

- (b) As of May 21, 2004, there were 308 holders of record of the Company's Common Stock.
- (c) The Company has not paid any cash dividends on its Common Stock since its inception, and intends to retain earnings, if any, for use in its business and for other corporate purposes. The Company is subject to certain agreements that restrict the payment of cash dividends.
- (d) Securities Authorized for Issuance Under Equity Compensation Plans:

	Number of securities to be issued upon exercise of outstanding options, warrants and rights	price of outstanding options,
	(a)	(b)
Equity compensation plans approved by security holders: 1993 Stock Incentive Plan 2003 Stock Incentive Plan	961 <b>,</b> 046 	\$.32 
Equity compensation plans not approved by security holders: Warrants issued to individuals for Monies loaned or services rendered Warrants issued in conjunction with Subordinated Mezzanine Debt	305,000 2,053,333	\$.49 \$.13
Subordinated Mezzanine Dept	2,033,333	ş.13 
Total	3,329,379 =======	\$.22 ====

Description of Equity Compensation Plans:

se av

is

(e refl

1993 Stock Incentive Plan

Under the 1993 Stock Incentive Plan, as amended ("1993 Plan"), options have been granted to officers, directors, consultants and employees of the Company and its subsidiaries to purchase the Company's common shares. Options granted under the 1993 Plan expire on various dates through 2013. There can be no further grants under the 1993 Plan.

Under the 1993 Stock Incentive Plan, option prices were at least 100% of the fair market value of the common stock at time of grant. For qualified employees, except under certain circumstances specified in the 1993 plan or unless otherwise specified at the discretion of the Board of Directors, no option may be exercised prior to one year after date of grant, with the balance becoming exercisable in cumulative installments over a three year period during the term of the option.

6

2003 Stock Incentive Plan

Under the 2003 Stock Incentive Plan ("2003 Plan"), options can be granted to officers, directors, consultants and employees of the Company and its subsidiaries to purchase up to 1,500,000 of the Company's common shares. No options were granted under the 2003 Plan during the Fiscal Year ended February 29, 2004.

Under the 2003 Stock Incentive Plan, option prices must be at least 100% of the fair market value of the common stock at time of grant. For qualified employees, except under certain circumstances specified in the 2003 plan or unless otherwise specified at the discretion of the Board of Directors, no option may be exercised prior to one year after date of grant, with the balance becoming exercisable in cumulative installments over a three year period during the term of the option.

Warrants Issued to Individuals for Monies Loaned or Services Rendered:

Warrants were issued in Fiscal Year February 28, 2000 to five individuals, including officers and directors, who loaned monies to the Company and one individual who assisted in raising funds for the Company. These warrants are for terms of five years with exercise prices ranging from \$.30 per share to \$1.00 per share. Warrants for 600,000 shares were exercised during the year ended February 29, 2004 at an average issuance price of \$.30. 300,000 of these warrants were exercised by the Chairman of the Company. The remaining warrants, held by three individuals are as follows; 5,000 which expired in April 2004; 225,000 which expire in August 2004; 25,000 which expire in January 2005; and 50,000 which expire in May 2005.

Warrants Issued in Conjunction with Subordinated Mezzanine Debt:

Warrants were issued to Norwood Venture Corporation in conjunction with \$850,000 in funding supplied to the Company. Stock purchase warrants (the "Put Warrants") to purchase 1,100,000 shares of the Company's common stock at an exercise price of \$.30, the fair market value of the Company's common stock on September 30, 1999. In connection with the amendments, dated December 22, 2000 and April 30, 2001, an additional 244,444 and 733,333 warrant shares were granted at exercise prices of \$0.30 and \$.10 per share, respectively. In connection with an amendment to the Norwood Agreement, in October 2001, the exercise price of certain of the warrants was reduced from \$.30 to \$.15 per share. During the year ended February 29, 2004 warrants for 24,444 shares at \$.10 per share were exercised. The Put Warrants can be put to the Company from May 29, 2006 to May 29, 2007 as defined by the Agreement, and they expire on September 30, 2010.

Under the Agreement, as amended, the Put date has been extended until the delivery of the February 29, 2008 financial statements and expires after the period of one year.

#### (e) Recent Sales of Unregistered Securities

In February 2004, the Company entered into agreements to exchange 578,035 shares of common stock valued at \$.42 per share with holders of notes of the Company valued at \$242,775. The exchanges were made in a private placement with four individuals who were accredited investors between February 9 and February 19, 2004. These issuances were deemed to be exempt from registration under the Securities Act of 1933 in reliance upon Section 4(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder.

ITEM 6 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

Certain statements made in this report may constitute "forward-looking statements" within the meaning of the Federal Securities Laws. Such forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management, and involve known and

7

unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among other things, the following:

- The Company's ability to respond to competition in its markets;
- General economic conditions in the Company's markets;

The Company undertakes no obligation to update publicly any forward-looking statement.

#### Overview

Sono-Tek has developed a unique and proprietary series of ultrasonic atomization nozzles, which are being used in an increasing variety of electronic, medical, industrial, and nanotechnology applications. These nozzles are electrically driven and create a fine, uniform, low velocity spray of atomized liquid particles, in contrast to common pressure nozzles. These characteristics create a series of commercial applications that benefit from the precise, uniform, thin coatings that can be achieved. When combined with significant reductions in liquid waste and less overspray than can be achieved with ordinary pressure nozzle systems, there is lower environmental impact.

The Company has a well established position in the electronics industry with its SonoFlux spray fluxing equipment. It saves customers from 40% to 80% of the liquid flux required to solder printed circuit boards over more labor intensive methods, such as foam fluxing. Less flux equates to less material cost, fewer chemicals in the workplace, and less clean-up. Also, the SonoFlux equipment reduces the number of soldering defects, which reduces the level of rework. The Company experienced a dramatic recovery of this market towards the latter part of this fiscal year, resulting in increased orders for our equipment.

In the past two years, the Company has focused engineering resources on the medical device market, with emphasis on providing coating solutions for the new generation of drug coated stents. The Company has sold a significant number of specialized ultrasonic nozzles and AccuMist(TM) stent coating systems to large pharmaceutical and medical device customers that are superior compared to pressure nozzles in their ability to uniformly coat the very small arterial stents without creating webs or gaps in the coatings. The Company has begun to sell a bench-top, fully outfitted stent coating system to a wide range of customers who are manufacturing stents or coatings to be used in developmental trials. The Company has developed a unique patented vacuum-based ultrasonic system capable of uniformly coating batches of stents with anti-restenosis coatings, and is now offering this technology to selected manufacturers for licensing. The Company's sales levels and sales potential of the business have increased as the result of an improved economy, product development efforts, and related marketing thrusts which have had the effects of improving net income, reducing debt, and bring shareholders' equity from a deficit position to a positive position.

8

#### Liquidity and Capital Resources

The Company's working capital was \$786,000 at February 29, 2004 up \$259,000 from \$527,000 at February 28, 2003. The increase in working capital was principally the result of increases in accounts receivables of \$440,000, inventory of \$111,000, partially offset by an increase in accounts payable and accrued expenses of \$293,000 The stockholders' equity increased \$1,226,000 to \$587,000 at February 29, 2004 compared to a deficit of \$639,000 at February 28, 2003. The increase in stockholders' equity was the result of the net income of \$785,000 (which included a \$585,000 tax benefit due to the recognition of a deferred tax asset), exercises of stock options and warrants of \$197,000 and the conversion of \$243,000 of notes and liabilities to equity. The Company has operated profitably for the last eleven fiscal quarters.

Accounts receivable at February 29, 2004 increased \$440,000, or 117%, from February 28, 2003 primarily due to \$420,000 more sales in the last month of the year ended February 29, 2004 as compared to the year ended February 28, 2003. The timing of sales orders is wholly dependent on customer delivery requirements

Inventory increased \$111,000, or 14%, as the result of new orders received towards the end of the fiscal year.

Accounts payable increased \$96,000 as compared to February 28, 2003 due to increased purchasing activity and to support new orders received towards the end of the fiscal year ended February 29, 2004.

The increase in accrued expenses of \$197,000 At February 29, 2004 compared the February 28, 2003 is principally due to increased customer deposits of \$106,000 and accrued sales representative commissions of \$95,000.

The Company currently has a \$350,000 line of credit with a bank. The loan is collateralized by accounts receivable, inventory and all other personal property of the Company, and is personally guaranteed by the former Chief Executive Officer of the Company. As of February 29, 2004, the outstanding balance was \$312,000.

The Company and it mezzanine lender, Norwood Venture Corporation reached an agreement in May 2004 which provides for the commencement of principal repayments of \$42,000 per month on November 30, 2005 for a period of 20 months,

as well as other changes in the terms of the loan agreement, including an extension of the put option period and modification of certain of the put option conditions. At February 29, 2004, \$840,000 of principal remained outstanding on the subordinated mezzanine loan.

Results of Operations

For the year ended February 29, 2004, the Company's sales increased \$344,000 or 11% to \$3,502,000, as compared to \$3,158,000 for the year ended February 28, 2003. The increase was a result of an increase in fluxing system sales, partially offset by a decrease nozzle-spraying system and specialty coating

9

system sales. The increase in fluxer sales was principally due to growing acceptance of the SonoFlux 2000F and orders for spare parts for the Company's other spray fluxing systems. The sales decrease in specialty coating system sales was caused by fewer orders placed for systems for national defense contracts.

The Company's gross profit increased \$222,000, to \$1,997,000 for the year ended February 29, 2004 from \$1,775,000 for the year ended February 28, 2003. The increase was primarily a result of higher sales of the Company's products. The mix of the Company's products sold did not affect the gross margin percentage, which marginally increased from 56% for the year ended February 28, 2003, to 57% for the year ended February 29, 2004.

Marketing and selling costs increased \$84,000 to \$700,000 for the year ended February 29, 2004 from \$616,000, for the year ended February 28, 2003. The increase was principally a result of increased sales commissions of \$47,000 and increased personnel costs of \$41,000. These increases were the direct result of increased sales levels during the current fiscal year.

Interest expense was reduced \$61,000 for the year ended February 29, 2004 as compared to the year ended February 28, 2003 as the result of repayments made and a drop in prevailing interest rates and \$57,000 less in imputed interest expense related to the Norwood loan warrant amortization in the current fiscal year.

Interest and other income decreased \$103,000 for the year ended February 29, 2004 as compared to February 28, 2003, as the prior year amount reflected profits realized from one-time settlements with vendors.

An income tax benefit of \$585,000 was reflected in the statement of operations as the result of recording a deferred tax asset relating to the tax effect of recognition of approximately \$1,500,000 of the Company's prior year net operating loss carryforwards.

The Company's net income from increased \$664,000 to \$785,000 or \$.07 per share on a diluted basis for the year ended February 29, 2004 from \$121,000 or \$0.01 per share for the year ended February 28, 2003.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon the Company's consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amount of assets and liabilities, revenues and expenses, and related disclosure on

contingent assets and liabilities at the date of the financial statements. Actual results may differ from these estimates under different assumptions and conditions.

10

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and may potentially result in materially different results under different assumptions and conditions. The Company believes that its critical accounting policies are limited to the one described below. For a detailed discussion on the application of this and other accounting policies see our note 2 to our consolidated financial statements.

#### Accounting for Income Taxes

As part of the process of preparing the consolidated financial statements, the Company is required to estimate income taxes. Management judgment is required in determining the provision for the deferred tax asset. The Company reduced the valuation reserve for the deferred tax asset resulting from net operating losses carried forward due to the Company having demonstrated consistent profitable operations.

#### Impact of New Accounting Pronouncements

In April 2003, the Financial Accounting Standards Board ("FASB") issued Statements of Financial Accounting Standards ("SFAS") No. 149, an amendment to SFAS No. 133. SFAS No. 149 clarifies under what circumstances a contract with initial investments meets the characteristics of a derivative and when a derivative contains a financing component. This SFAS is effective for contracts entered into or modified after June 30, 2003.

In May 2003, the FASB issued SFAS No. 150, which established standards for how an issuer classifies and measures in its statement of financial position certain financial instruments with characteristics of both liabilities and equity. It requires that an issuer classify a financial instrument that is within its scope as a liability (or an asset in some circumstances) because that financial instrument embodies an obligation of the issuer. This SFAS is effective for financial instruments entered into or modified after May 31, 2003 and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. It is to be implemented by reporting the cumulative effect of a change in accounting principle for financial instruments created before the issuance date of SFAS No. 150 and still existing at the beginning of the interim period of adoption. Restatement is not permitted. The adoption of SFAS No. 150 only required the Company to have additional disclosures regarding the Put Warrants and did not have a material effect on the financial statements. The Company adopted SFAS No. 150 in the first quarter of fiscal 2004.

In December 2003, the FASB revised SFAS No. 132 Employers' Disclosures about Pensions and Other Post Retirement Benefits. This revision requires additional disclosures to those in the original SFAS No. 132 about assets, obligations, cash flows and net periodic benefit cost of deferred benefit pension plans and other deferred benefit post-retirement plans. The required information should be provided separately for pension plans and for other post-retirement benefit plans. This statement revision is effective for fiscal year ending after December 14, 2003 and interim periods beginning after December 15, 2003. The adoption of this revision is not expected to have a material impact on our results of operations, financial position or disclosures.

ITEM 7 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

See pages 20 to 38.

ITEM 8 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

(a) There were no changes in and disagreements with Accountants on Accounting and Financial Disclosure.

#### ITEM 8A CONTROLS AND PROCEDURES

- (a) Evaluation of disclosure controls and procedures. The Company has established and maintains "disclosure controls and procedures" (as those terms are defined in Rules 13a -14(c) and 15d- 14(c) under the Securities and Exchange Act of 1934 (the "Exchange Act'). Christopher L. Coccio, President and Chief Operating Officer (principal executive and accounting officer) of the Company has evaluated the Company's disclosure controls and procedures within 90 days of filing this Form 10-KSB. Based on his evaluation, Mr. Coccio has concluded that the Company's disclosure controls and procedures are effective to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by SEC rules and Forms.
- (b) There were no significant changes in the Company's internal controls or in other factors that could significantly affect these controls after the date of their evaluations. There were no significant deficiencies or material weaknesses, and therefore there were no corrective actions taken.

#### PART III

#### ITEM 9 DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

(a) Identification of Directors

Name	Age	Position with the Company
Harvey L. Berger Christopher L. Coccio	65 63	Director and Chief Technologist Chief Executive Officer, President and a Director
Donald F. Mowbray Samuel Schwartz	66 84	Director* Chairman and Director*

<sup>\*</sup> Member of the Audit Committee and Compensation Committee.

12

The Board of Directors is divided into two classes, which were established by the Company's shareholders at their annual meeting held on October 19, 1989. The directors in each class serve for a term of two years. The terms of the classes are staggered so that only one class of directors is elected at each annual meeting of the Company. The terms of Messrs. Schwartz and Mowbray run until the annual meeting to be held in 2004, and the terms of Drs. Berger and Coccio run until the annual meeting to be held in 2005, and in each case until their respective successors are duly elected and qualified.

#### (b) Identification of Executive Officers

Name	Age	Position with the Company
Christopher L. Coccio	63	Chief Executive Officer, President and Director
Vincent F. DeMaio	66	Vice President
R. Stephen Harshbarger	36	Vice President

The foregoing officers are elected for terms of one year or until their successors are duly elected and qualified or until terminated by the action of the Board of Directors. There are no arrangements or understandings between any executive officer and any other persons(s) pursuant to which he was or is to be selected as an officer.

(c) Identification of Certain Significant Employees

Not applicable.

(d) Family Relationships

None.

(e) Business Experience

DR. HARVEY L. BERGER has been a Director of the Company since June 1975. He was appointed Chief Technologist in April 2001. He was President of the Company from November 1981 to September 1984 and from September 1985 until April 2001. From September 1986 to September 1988, he also served as Treasurer. He was Vice Chairman of the Company from March 1981 to September 1985. Dr. Berger holds a Ph.D. in physics from Rensselaer Polytechnic Institute and is a member of the Marist College Advisory Board.

DR. CHRISTOPHER L. COCCIO has been a Director of the Company since June 1998. From 1964 to 1996, he held various engineering, sales, marketing and management positions at General Electric Company, with P&L responsibilities for up to \$100 million in sales and 500 people throughout the United States. His business experience includes both domestic and international markets and customers. He founded a management consulting business in 1996, and worked with the New York State Assembly's Legislative Commission on Science and Technology from 1996 to 1998. From 1998 to 2001, he worked with Accumetrics Associates, Inc., a

13

manufacturer of digital wireless telemetry systems, as Vice President of Business Development and member of the Board of Advisors. Mr. Coccio received a B.S.M.E. from Stevens Institute of Technology, a M.S.M.E. from the University of Colorado, and a Ph.D. from Rensselaer Polytechnic Institute in Chemical Engineering. He was appointed President and Chief Executive Officer of Sono-Tek on April 30, 2001.

VINCENT F. DEMAIO has been Vice President of Manufacturing of the Company since March 2003. He joined the Company in August 1991 as Production Manager and has served as Field Service Manager and Director of Operations. Prior to joining the Company Mr. DeMaio was an independent real estate developer from 1987 to 1991. From 1956 to 1987, Mr. DeMaio was employed by IBM Corporation in various manufacturing positions the last being Manufacturing Supervisor over 600 employees.

R. STEPHEN HARSHBARGER has been Vice President of the Company since June 2000. He joined the Company in October 1993 as a Sales Engineer and served in various sales management capacities from 1997 to 2000. Prior to joining the Company, Mr. Harshbarger was the Sales and Marketing Coordinator at Plasmaco, Inc., a developer and manufacturer of state-of-the-art flat panel displays. He is a graduate of Bentley College, with a major in Finance and a minor in Marketing.

DR. DONALD F. MOWBRAY has been a Director since August 2003. He has been an independent consultant since August 1997. From September 1992 to August 1997 he was the Manager of the General Electric Company's Corporate Research and Development Mechanical Engineering Laboratory. From 1962 to 1992 he worked for the General Electric Company in a variety of engineering and managerial positions. Dr. Mowbray received a B.S. in Aeronautical Engineering from the University of Minnesota in 1960, a Master of Science in Engineering Mechanics from the University of Minnesota in 1962 and a Ph.D. from Rensselaer Polytechnic Institute in Engineering Mechanics in 1968.

SAMUEL SCHWARTZ has been a Director of the Company since August 1987, and was Chairman of the Board from February 1993 to May 1999. In April 2001, he accepted the position as Acting Chairman of the Board. He became Chairman in August 2001. From 1959 to 1992, he was the Chairman and Chief Executive Officer of Krystinel Corporation, a manufacturer of ceramic magnetic components used in electronic circuitry. He received a B.CH.E. from Rensselaer Polytechnic Institute in 1941 and a M.CH.E. from New York University in 1948.

Section 16(a) Beneficial Ownership Reporting Compliance

The Company is not aware of any reports required by section 16(a) that were not filed on a timely basis.

14

#### ITEM 10 EXECUTIVE COMPENSATION

The following table sets forth the aggregate remuneration paid or accrued by the Company for Fiscal Years ended February 28, 2004, 2003 and 2002, for each named officer of the Company. No other executive officer received aggregate remuneration that equaled or exceeded \$100,000 for the Fiscal Year ended February 29, 2004.

#### SUMMARY COMPENSATION TABLE

		7		Long Term Compensation Awards	
Name and Principal Position	Year 	Annual Com Salary (\$)	pensation  Bonus (\$) 	Securities Underlying Options (#)	All Othe
Christopher L. Coccio	2004	\$129 <b>,</b> 970	\$17 <b>,</b> 500	0	\$1,244
CEO, President and	2003	\$124,462	\$7 <b>,</b> 500	275,000	\$1,260
Director	2002(2)	\$92 <b>,</b> 354	\$40,000	200,000	\$178
R. Stephen Harshbarger	2004	\$105 <b>,</b> 854	\$4 <b>,</b> 375	0	\$927
Vice-President	2003	\$88,196	\$1,200	20,000	\$996
	2002	\$90 <b>,</b> 520	\$5 <b>,</b> 000	15,000	\$207

- (1) Dollar amounts are Company contributions under the Company's retirement plan.
- (2) Dr. Coccio became an employee of the Company as of May 7, 2001.

The following table sets forth information regarding option grants made during the last completed fiscal year for each named officer of the Company.

Option/SAR Grants in Last Fiscal Year

Number of	Percent of total		
Securities	options/SARs		
Underlying	granted to		
Options/SARs	employees in	Exercise or base	
granted (#)	fiscal year	price (\$/Sh)	Expiration dat

#### None

Name

The following table sets forth information regarding option exercises during the Fiscal Year ended February 29, 2004, as well as any unexercised options held as of February 29, 2004 by each named executive who received in excess of \$100,000 in salary and bonus.

Aggregate Option/SAR Exercises in Last Fiscal Year and Fiscal Year End Option/SAR Values

			Number of Securities Underlying Unexercised Options		
	Shares Acquired on	Value	at Fiscal	Year End (#)	At
Name	Exercise (#)	Realized (\$)	Exercisable	Unexercisable	Exer
Christopher Coccio	39,766	0	455,234	0	\$2
R. Stephen Harshbarger	0	0	85,000	0	\$

15

#### Audit Committee

The Company's Board of Directors has an Audit Committee composed of Samuel Schwartz and Donald F. Mowbray. The Audit Committee is responsible for (i) selecting an independent public accountant for ratification by the stockholders, (ii) reviewing material accounting items affecting the consolidated financial statements of the Company, and (iii) reporting its findings to the Board of Directors. The Company does not have a person designated as a "financial expert" serving on its Audit Committee because it has had difficulty finding a qualified person, but continues to actively seek out such an individual.

Compensation Committee Interlocks and Insider Participation

The Company's Board of Directors has a Compensation Committee composed of Samuel Schwartz and Donald F. Mowbray. However, the Compensation Committee serves an advisory function only. All decisions regarding compensation are made by the full Board of Directors.

16

#### ITEM 11 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following information is furnished as of May 21, 2004, to indicate beneficial ownership of the Company's Common Stock by each Director, by each named executive officer who has a salary and bonus in excess of \$100,000, by all Directors and executive officers as a group, and by each person known to the Company to be the beneficial owner of more than 5% of the Company's outstanding Common Stock. Such information has been furnished to the Company by the indicated owners. Unless otherwise indicated, the named person has sole voting and investment power.

Name (and address if more than 5%) of Beneficial owner	Amount Beneficially Owned	Percent
Directors and Officers		
*Harvey L. Berger	386,700(1)	3.6%
*Christopher L. Coccio	483,333(2)	4.6%
*R. Stephen Harshbarger	85,000(3)	* *
*Donald F. Mowbray	20,000(4)	**
*Samuel Schwartz	1,564,557(5)	14.3%
All Executive Officers and Directors as a Group (6)	2,623,158(6)	24.58%
Additional 5% owners		
Herbert Spiegel	766,341(7)	7.0%
425 East 58th Street		
New York, NY 10022		
Norwood Venture Corporation 65 Norwood Avenue Montclair, NJ 07043	1,548,035(8)	14.1%

- \* c/o Sono-Tek Corporation, 2012 Route 9W, Milton, NY 12547.
- \*\* Less than 1%
- (1) Includes 4,000 shares in the name of Dr. Berger's wife and 65,000 options currently exercisable issued under the 1993 Plan.
- (2) Includes 20,000 options currently exercisable issued under the 1993 Plan.
- (3) Includes 7,500 options currently exercisable under the 1993 Plan.
- (4) Includes 20,000 options currently exercisable issued under the 1993Plan.
- (5) Includes 40,000 options currently exercisable issued under the 1993 Plan and 252,649 warrants currently exercisable issued on April 30, 2001 in conjunction with a loan made to the Company.
- (6) Includes 225,500 options currently exercisable issued under the 1993 Plan and 252,649 warrants issued on April 30, 2001 in conjunction with a loan made to the Company. Does not include 65,000 options under the 2003Plan which are not currently exercisable.
- (7) Includes 252,649 warrants currently exercisable issued on April 30, 2001 in conjunction with a loan made to the Company.
- (8) Includes 1,100,000 warrants currently exercisable issued on September 30, 1999, 244,444 warrants currently exercisable issued on December 20, 2000, and 203,591 warrants currently exercisable issued on April 30, 2001, all in conjunction with a loan, as amended, made to the Company.

17

#### ITEM 12 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Norwood loans - On April 30, 2001, in order to induce the advance of an additional \$300,000 by Norwood, certain of the Company's directors, an officer and an affiliate of the Company participated in the amount of \$216,750 in the additional mezzanine financing. Interest expense of \$103,617 was paid to Norwood and \$26,571 was forwarded to these individuals during Fiscal Year 2004. During February 2004, an officer of the Company exercised 24,444 warrants to purchase the Company's common stock through Norwood. Coincident with this transaction \$10,000 of principal loaned by Norwood was repaid and was in turn repaid to this officer.

Debt Exchange - related party -

During February 2004 loans, accrued interest and prior year consulting fees due to the Chairman of the Company in the amount of \$123,827 were exchanged for 294,825 shares of common stock valued at \$.42 per share. The debt to equity conversion price was negotiated independently with other third party creditors on an "arms length" basis.

Warrant issuance - related party-

During February 2004 warrants to acquire 300,000 shares of the Company's common stock were exercised at \$.30 per share by the Chairman of the Company for \$90,000. The proceeds from this exercise were used to repay prior year loans due to the Chairman.

- ITEM 13 EXHIBITS, CONSOLIDATED FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
- (a) (1) The consolidated financial statements and schedules listed in the accompanying "Index to Consolidated Financial Statements" are filed as a part of this annual report.
- (2) See (a) (1) above.
- (3) Exhibits

Ex. No.	Description
3(a)(1)	Certificate of Incorporation of the Company and all amendments thereto.
3(b)(1)	By-laws of the Company as amended.
4(a)(3)	Form of Warrant.
4(b)(3)	Master Security Agreement.
4(c)(4)	Letter agreement between the Company and The Bank of New York.
4(d)(5)	Former CEO's Personal Guarantee for the Bank of New York.
4(e)(2)	Note and Warrant Purchase Agreement dated September 29, 1999 by
	and between the Company and Norwood Venture Corp.
4(f)(2)	Note issued by the Company, dated September 29, 1999, in the
	principal sum of \$450,000.

18

4(g) (2) Common Stock Purchase Warrant, dated September 29, 1999, issued by the Company to Norwood Venture Corp.

- 4(h)(2) General Security Agreement, dated September 29, 1999, issued by the Company in favor of Norwood Venture Corp.
  4(i)(7) Amended, Note and Warrant Purchase Agreements dated December 22, 2000 and April 30, 2001 by and between the Company and Norwood Venture Corp.
  4(j)(8) Amended Note and Warrant Purchase Agreement dated October 24, 2001
- 4(j)(8) Amended Note and Warrant Purchase Agreement dated October 24, 200 between the Company and Norwood Venture Corp.
- 10(a)(6) Lease for the Company's facilities in Milton, NY dated December 1, 1999.
- 10(b)(1) Sono-Tek Corporation 1993 Stock Incentive Plan as amended.
- 10(c)(1) Sono-Tek Corporation 2003 Stock Incentive Plan.
- 10(d)(6) Bank of New York Line of Credit.
- 14 Code of Ethics.
- 21(9) Subsidiaries of Small Business Issuer.
- 23.1 Independent Auditors' Consent.
- 31 Rule 13a-14/15d 14(a) Certification.
- 32 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
- (1) Incorporated herein by reference to the Company's Registration Statement No. 333-11913 on Form S-8 filed on February 18, 2004.
- (2) Incorporated herein by reference to the Company's Form 10-Q Quarterly Report for the quarter ended November 30, 1999.
- (3) Incorporated herein by reference to the Company's Form 10-Q Quarterly Report for the quarter ended November 30, 1993.
- (4) Incorporated herein by reference to the Company's Form 10-Q quarterly report for the quarter ended May 31, 1996.
- (5) Incorporated herein by reference to the Company's Form 10-K for the year ended February 28, 1999.
- (6) Incorporated herein by reference to the Company's Form 10-K for the year ended February 29, 2000.
- (7) Incorporated herein by reference to the Company's Form 10-K for the year ended February 28, 2001.
- (8) Incorporated herein by reference to the Company's Form 10-QSB quarterly report for the quarter ended November 30, 2001.
- (9) Incorporated herein by reference to the Company's Form 10-KSB for the year ended February 28, 2003.
- (b) Reports on Form 8-K.

Report on Form 8-K filed January 6, 2004, relating to an earnings release. Report on Form 8-K filed February 27, 2004, relating to an exchange of debt.

#### ITEM 14 DISCLOSURE OF FEES PAID TO PRINCIPAL ACCOUNTANTS

For the Fiscal Years ended February 29, 2004 and February 28, 2003 the Company paid or accrued fees of approximately \$31,000\$ and \$29,000 for services rendered by Radin Glass & Co., LLP, its independent auditors. These fees included audit services and tax return preparation.

There were no other fees for services rendered by Radin Glass & Co. other than for services described above.

19

SONO-TEK CORPORATION

FORM 10-KSB

ITEM 7

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SCHEDULES

FOR THE YEAR ENDED FEBRUARY 29, 2004

INDEPENDENT AUDITORS' REPORT

CONSOLIDATED FINANCIAL STATEMENTS:

Consolidated Balance Sheet at February 29, 2004

Consolidated Statements of Operations
For the Years Ended February 29, 2004 and February 28, 2003

Consolidated Statements of Stockholders' (Deficiency) Equity For the Years Ended February 29, 2004 and February 28, 2003

Consolidated Statements of Cash Flows
For the Years Ended February 29, 2004 and February 28, 2003

Notes to the Consolidated Financial Statements

20

#### INDEPENDENT AUDITORS' REPORT

To the Stockholders and Board of Directors Sono-Tek Corporation Milton, New York

We have audited the accompanying consolidated balance sheet of Sono-Tek Corporation as of February 29, 2004, and the related consolidated statements of operations, stockholders' equity and cash flow for each of the two years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audit in accordance with auditing standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Sono-Tek Corporation, as of February 29, 2004 and the results of their operation and their cash flows for each of the two years then ended in conformity with accounting principles generally accepted in the United States.

New York, New York April 27, 2004, except as to Note 16 which date is May 13, 2004.

21

### SONO-TEK CORPORATION CONSOLIDATED BALANCE SHEET

#### ASSETS

ASSEIS	
	February 29, 2004
Current Assets	
Cash and cash equivalents	\$ 189,987
Accounts receivable (less allowance of \$15,046)	813,835
Inventories	905,469
Prepaid expenses and other current assets	83 <b>,</b> 599
Deferred tax asset	117,000
Total current assets	2,109,890
Equipment, furnishings and leasehold improvements	
(less accumulated depreciation of \$675,795)	57 <b>,</b> 835
Intangible assets, net	31,050
Other assets	6,542
Deferred tax asset	468,000
TOTAL ASSETS	\$ 2,673,317
	========
LIABILITIES AND STOCKHOLDERS' EQUITY	
Current Liabilities:	
Accounts payable	\$ 245 <b>,</b> 981
Accrued expenses	441,117
Line of credit	312,000
Subordinated mezzanine debt	282,144
Current maturities of long term debt	42 <b>,</b> 189
Total current liabilities	1,323,431
Subordinated mezzanine debt	557 <b>,</b> 856
Long term debt, less current maturities	16,960
Total liabilities	1,898,247
Commitments and Contingencies Put Warrants	 188 <b>,</b> 223
Stockholders' Equity Common stock, \$.01 par value; 25,000,000 shares authorized,	
10,494,156 issued and outstanding	104,942
Additional paid-in capital	6,465,436
Accumulated deficit	(5,983,531)
Total stockholders' equity	586 <b>,</b> 847
Total Stockholders equity	

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

\$ 2,673,317 =======

See notes to consolidated financial statements.

22

#### SONO-TEK CORPORATION

# CONSOLIDATED STATEMENTS OF OPERATIONS

	Years E	Inded
	February 29, 2004	February 28, 2003
Net Sales Cost of Goods Sold	\$ 3,501,594 1,505,010	\$ 3,157,756 1,382,676
Gross Profit	1,996,584	1,775,080
Operating Expenses Research and product development Marketing and selling General and administrative Total Operating Expenses	365,577 700,445 571,058 1,637,080	361,783 615,736 556,260 1,533,779
Operating Income	359,504	241,301
Interest Expense Interest and Other Income	(166,884) 8,719	(228,488) 111,228
<pre>Income before Income Taxes Income Tax Benefit (Expense)</pre>	201,339 583,890	124,041 (3,085)
Net Income	\$ 785,229	\$ 120,956
Basic Earnings Per Share	\$ .08	\$ .01
Diluted Earnings Per Share	\$ .07	\$ .01
Weighted Average Shares - Basic	9,248,175	9,152,401
Weighted Average Shares - Diluted	11,414,584 ======	10,265,644 =======

See notes to consolidated financial statements.

23

# SONO-TEK CORPORATION CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIENCY) EQUITY YEARS ENDED FEBRUARY 29, 2004 AND FEBRUARY 28, 2003

	Common Stock Par Value \$.01				Total Stockhol
	Shares	Amount		Accumulated Deficit	(Deficie Equit 
Balance - February 28, 2002	9,105,422	\$ 91,055	\$6,016,107	\$(6,889,716)	(\$782 <b>,</b> 5
Issuance of common stock	94,739	947	17,053		18,0
Imputed interest - affiliate loan			4,145		4,1
Net Income				120,956	120,9
Balance - February 28, 2003	9,200,161	92,002	6,037,305	(6,768,760)	(639,4
Non-employee stock options			1,564		1,5
Exercise of warrants	624,444	6,245	176,200		182,4
Exercise of stock options	91,516	915	13,372		14,2
Conversion of notes and liabilities		5,780			242,7
Net Income	·		·	785 <b>,</b> 229	785 <b>,</b> 2
Balance - February 29, 2004	10,494,156	\$104,942	\$6,465,436	\$(5,983,531)	 \$ 586,8
- '		=======	========		

See notes to consolidated financial statements.

24

# SONO-TEK CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS

	Years Ended		
	February 29, 2004	February 2003	
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net Income	\$ 785,229	\$ 120 <b>,</b> 9	
Adjustments to reconcile net income to net			
cash provided by (used in) operating activities:			
Depreciation and amortization	49,469	76 <b>,</b> 5	
Imputed interest expense	17,608	74 <b>,</b> 6	
Provision for doubtful accounts	1,371	(11,3	
(Increase) decrease in:			
Accounts receivable	(440,166)	16,3	
Inventories	(110,803)	(25,9	
Prepaid expenses and other current assets	(27,577)	12,3	
Deferred tax assets	(585,000)		

<pre>Increase (decrease) in:</pre>		
Accounts payable and accrued expenses	292 <b>,</b> 892	(144 <b>,</b> 3
Net Cash (Used In) Provided By Continuing Operations Net Cash (Used In) Provided By Discontinued Operations	(16,977) 	119,3 (167,4
Net Cash (Used In) Provided By Operating Activities	(16,977)	(48,0
CASH FLOWS FROM INVESTING ACTIVITIES:  Sale (purchase) of equipment, furnishings and leasehold improvements Patent filing costs Other assets	(10,411) (2,296) 	(8,1 (13,9 1,1
Net Cash (Used In) Provided By Continuing Operations	(12,707)	(21,0
Net Cash (Used In) Provided By Investing Activities	(12,707)	(21,0
CASH FLOWS FROM FINANCING ACTIVITIES:  Proceeds from issuance of stock Proceeds from exercise of warrants and options Conversion of notes and debt to equity Repayment under revolving credit line Repayments of notes payable and equipment loans Repayment of notes to related parties Repayment of subordinated debt Loan Payments/ exchanges Payment of long-term liabilities	198,296 242,774 —— (9,072) (24,283) (20,928) (432,774) ——	18,0 (32,0 (22,6 (46,1 (5,8 (29,6
Net Cash (Used in) Provided by Continuing Operations Net Cash (Used in) Discontinued Operations	(45,987) 	(118,4
Net Cash Used in Financing Activities	(45,987)	(118,4
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS Beginning of year	(75,671) 265,658	(187,5 453,2
End of year	\$ 189,987	 \$ 265,6

See notes to consolidated financial statements.

25

SONO-TEK CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED FEBRUARY 29, 2004 AND FEBRUARY 28, 2003

#### NOTE 1: BUSINESS DESCRIPTION

The Company was incorporated in New York on March 21, 1975 for the purpose of engaging in the development, manufacture, and sale of ultrasonic liquid atomizing nozzles. Ultrasonic nozzle systems atomize low to medium viscosity liquids by converting electrical energy into mechanical motion in the form of high frequency ultrasonic vibrations that break liquids into minute drops that can be applied to surfaces at low velocity.

#### NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

Consolidation - The accompanying consolidated financial statements of Sono-Tek Corporation, a New York corporation (the "Company"), include the accounts of the Company and its wholly owned subsidiary, Sono-Tek Cleaning Systems, Inc., a New Jersey Corporation ("SCS"), which the Company acquired on August 3, 1999, whose operations have been discontinued. All significant intercompany accounts and transactions are eliminated in consolidation.

Cash and Cash Equivalents - Cash and cash equivalents consist of money market mutual funds and short-term certificates of deposit with original maturities of 90 days or less. The Company occasionally has cash or cash equivalents on hand in excess of the \$100,000 insurable limits at a given bank. At February 29, 2004, the Company had \$79,524 over the insurable limit.

Supplemental Cash Flow Disclosure -

Years Ended		
February 29, 2004	February 28, 2003	
\$172 <b>,</b> 684	\$168,644	
\$ 17,606	\$ 70,521	
	\$ 4,145 ======	
	\$ 18,000 ======	
	February 29, 2004 \$172,684 \$ 17,606	

Inventories - Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method for raw materials, subassemblies and work-in-progress and the specific identification method for finished goods. Consignment goods are spare parts used by outside sales representatives for emergency repairs performed on customer's equipment.

26

Equipment, Furnishings and Leasehold Improvements - Equipment, furnishings and leasehold improvements are stated at cost. Depreciation of equipment and furnishings is computed by use of the straight-line method based on the estimated useful lives of the assets, which range from three to five years.

Product Warranty - Expected future product warranty expense is recorded when the product is sold.

Intangible Assets - Include Costs of patent applications which are deferred and charged to operations over seventeen years for domestic patents and twelve years for foreign patents and the unamortized portion of deferred financing costs. The accumulated amortization of patents is \$41,132 at February 29, 2004. Deferred financing fees of \$35,523 at February 24, 2004 are being amortized over the term of the related debt. Accumulated amortization was \$31,376 at February 29, 2004.

Research and Product Development Expenses - Research and product development expenses represent engineering and other expenditures incurred for developing

new products, for refining the Company's existing products and for developing systems to meet unique customer specifications for potential orders or for new industry applications and are expensed as incurred. Engineering costs directly applicable to the manufacture of existing products are included in cost of goods sold.

Income Taxes - The Company accounts for income taxes under the asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences of "temporary differences" by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized.

Earnings (Loss) Per Share - Basic earnings (loss) per share ("EPS") is computed by dividing net income (loss) by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Stock options granted but not yet exercised under the Company's stock option plans are included for Diluted EPS calculations under the treasury stock method.

Advertising Expenses - The Company expenses the cost of advertising in the period in which the advertising takes place.

Long-Lived Assets - The Company periodically evaluates the carrying value of long-lived assets, including intangible assets, when events and circumstances warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated undiscounted cash flow from such asset is separately identifiable and is less than its carrying value. In that event, a

27

loss is recognized based on the amount by which the carrying value exceeds the fair market value of the long-lived asset. Fair market value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved.

Stock-Based Employee Compensation - The Company accounts for stock-based compensation plans utilizing the provisions of Accounting Principles Board Opinion No. 25 (APB 25), "Accounting for Stock Issued to Employees" and the Financial Accounting Statement of Financial Accounting Standards No. 123 (SFAS 123), "Accounting for Stock-Based Compensation". Under SFAS 123, the Company will continue to apply the provisions of APB 25 to its stock-based employee compensation arrangements, and is only required to supplement its financial statements with additional proforma disclosures.

Recognition of Revenue - Sales are recorded at the time title passes to the customer, which, based on shipping terms, generally occurs when the product is shipped to the customer. Based on prior experience, the Company reasonably estimates its sales returns and warranty reserves.

Management Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Pronouncements-

In April 2003, the Financial Accounting Standards Board ("FASB") issued Statements of Financial Accounting Standards ("SFAS") No. 149, an amendment to SFAS No. 133. SFAS No. 149 clarifies under what circumstances a contract with initial investments meets the characteristics of a derivative and when a derivative contains a financing component. This SFAS is effective for contracts entered into or modified after June 30, 2003.

In May 2003, the FASB issued SFAS No. 150, which established standards for how an issuer classifies and measures in its statement of financial position certain financial instruments with characteristics of both liabilities and equity. It requires that an issuer classify a financial instrument that is within its scope as a liability (or an asset in some circumstances) because that financial instrument embodies an obligation of the issuer. This SFAS is effective for financial instruments entered into or modified after May 31, 2003 and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. It is to be implemented by reporting the cumulative effect of a change in accounting principle for financial instruments created before the issuance date of SFAS No. 150 and still existing at the beginning of the interim period of adoption. Restatement is not permitted. The adoption of SFAS No. 150 only required the Company to have additional disclosures regarding the Put Warrants and did not have a material effect on the financial statements. The Company adopted SFAS No. 150 in the first quarter of fiscal 2004.

28

In December 2003, the FASB revised SFAS No. 132 Employers' Disclosures about Pensions and Other Post Retirement Benefits. This revision requires additional disclosures to those in the original SFAS No. 132 about assets, obligations, cash flows and net periodic benefit cost of deferred benefit pension plans and other deferred benefit post-retirement plans. The required information should be provided separately for pension plans and for other post-retirement benefit plans. This statement revision is effective for fiscal year ending after December 14, 2003 and interim periods beginning after December 15, 2003. The adoption of this revision is not expected to have a material impact on our results of operations, financial position or disclosures

# NOTE 3: SEGMENT INFORMATION

The Company currently operates in one business segment, spraying systems and is primarily engaged in the business of developing, manufacturing, selling, installing and servicing ultrasonic spray equipment.

#### NOTE 4: INVENTORIES

Inventories consist of the following:

	February 29, 2004
Raw Materials	\$ 348,965
Work-in-process	325,460
Consignment	5 <b>,</b> 379
Finished Goods	422,197
Totals	1,102,001
Less: Allowance	(196,532)
	\$ 905,469
	========

#### NOTE 5: EQUIPMENT, FURNISHINGS AND LEASEHOLD IMPROVEMENTS

Equipment, furnishings and leasehold improvements consist of the following:

	February 29, 2004
Laboratory equipment	\$ 82,395
Machinery and equipment	394,412
Leasehold improvements	44,513
Furniture and fixtures	212,310
Totals	733,630
Less: accumulated depreciation	(675,795)
	\$ 57,835
	=======

29

#### NOTE 6: ACCRUED EXPENSES

Accrued expenses consist of the following:

	February 29, 2004
Accrued compensation	\$122,664
-	14,338
Sales tax liability	•
Accrued interest	10,561
Accrued marketing expense	22,215
Estimated warranty costs	13,350
Accrued commissions	103,840
Professional fees	21,590
Customer deposits	113,173
Other accrued expenses	19,386
	\$441,117
	=======

# NOTE 7: REVOLVING LINE OF CREDIT

The Company has a \$350,000 revolving line of credit that carries an interest rate of prime plus 2% (6.00% at February 29, 2004). The loan is collateralized by accounts receivable, inventory and all other personal property of the Company and is guaranteed by the former CEO of the Company. The line of credit is payable on demand. As of February 29, 2004, the balance was \$312,000.

30

#### NOTE 8: LONG-TERM DEBT

Long-term debt of continuing operations consists of the following:

February 29, 2004

Notes payable to related parties, payable monthly In installments of \$474 plus monthly interest of 5% over 48 months through March 31, 2006.	\$ 20,395
Equipment loan, bank, collateralized by related production equipment, payable in monthly installments of principal of \$756 plus interest at 2% over the bank's prime rate (6.00% at February 29, 2004) through May 2005.	11,340
Subordinated loans to former owners of acquired business, payable in monthly installments of principal of \$1,500 and interest at 6%.	27,414
Total long term debt Due within one year	59,149 (42,189)
Due after one year	\$ 16,960 ======
Long-term debt is payable as follows (as of February 29, 2004): Fiscal Year ending February,	
2005 2006	\$ 42,189 16,960
	\$ 59,149 ======

#### NOTE 9: SUBORDINATED MEZZANINE DEBT

On September 30, 1999, the Company entered into a 12%, \$450,000 Note and Warrant Purchase Agreement with Norwood Venture Corporation ("Norwood Note") less a proportionate equity share of the greatest of three different valuations of the Company upon exercise of the Put Warrants. On December 22, 2000, Norwood amended the Note and Warrant Purchase Agreement ("Agreement") to increase the note to \$550,000. On April 30, 2001, Norwood amended the Agreement to increase the note by \$300,000 to \$850,000 and the warrant shares to 2,077,777. In connection with this additional loan, \$50,000 of advances from certain shareholders and directors was repaid (See note 20). The Norwood Note, as amended, requires interest payments through September 2002, followed by monthly principal payments of \$23,612 and interest through September 2005. The Norwood Note is collateralized by certain assets of the Company. The Norwood Note, among other things, restricts the payment of dividends.

31

In addition, the original Norwood Note was issued with a detachable stock purchase warrant (the "Put Warrants") to purchase 1,100,000 shares of the Company's common stock at an exercise price of \$.30, the fair market value of the Company's common stock on September 30, 1999. The fair market value, as determined by an independent appraisal, of the Put Warrants was determined to be \$0.07 per share, and is accounted for as a discount to the Norwood Note and will be amortized over the life of the principal repayment term of the Agreement. In connection with the amendments, dated December 22, 2000 and April 30, 2001, an additional 244,444 and 733,333 warrant shares were granted at an exercise price of \$0.30 and \$.10 per share, respectively. In connection with an amendment to the Agreement in October 2001, the exercise price of certain of the warrants was reduced from \$.30 to \$.15 per share. This resulted in an increase in the value

of the warrants of \$13,445, which is accounted as a discount to the loan and is being imputed as additional interest over the term of the loan. The discount was fully amortized at February 29, 2004.

The Put Warrant holders may, commencing after the delivery of the February 28, 2006 audited financial statements and terminating one year thereafter, require the Company to purchase such warrants at a price equal to the result calculated by subtracting the aggregate exercise of the warrants to the extent remaining from the product of the greatest of:

- a) The fair market value of the Company as determined by an independent appraiser as at the end of the Company's fiscal year end February 28, 2006 (the "Company's 2006 Fiscal Year"),
- b) five times EBITDA for the Company's 2006 Fiscal Year or, if higher, average EBITDA for such year and the fiscal year of the Company immediately prior to such year, or
- c) the book value of the Company as at the end of the Company's 2006 Fiscal Year,

multiplied by the fraction of (the "Put Fraction") the numerator of which is the total number of shares of common stock the Put Warrant holders would own upon such exercise of the warrants and the denominator would be the total number of common shares outstanding upon the exercise of all equity rights to acquire common stock. The Norwood Agreement provides for pre-emptive rights to purchase equity from the Company at the most favorable terms offered to others.

If the Company, based upon its fair value computed using its Fiscal Year 2006 results, is required to pay the Put under the warrants, warrant holders will have to pay up to \$275,000 for the warrants. Upon measurement and exercise, one third of such put payment by the Company would be due immediately, with the balance payable over 36 months with interest at 12%.

The deferred financing fees of \$35,523 incurred to acquire the Norwood Note are being amortized over the life of the loan. Accumulated amortization of the deferred financing fees was \$31,376 at February 29, 2004.

32

# NOTE 10: COMMITMENTS AND CONTINGENCIES

Leases - Total rent expense was approximately \$78,661 and \$78,447, for the two years ended February 29, 2004 and February 28, 2003, respectively.

The Company has \$138,485 in future minimum obligations under its lease, which expires November 30, 2005.

#### NOTE 11: INCOME TAXES

The annual provision (benefit) for income taxes differs from amounts computed by applying the maximum U.S. Federal income tax rate to pre-tax income (loss) as follows:

	February 29,		February 28,	
	2004	%	2003	%
Computed tax at maximum rate Other permanent differences	68,455 1,728	34.0 1.0	\$41,125 2,440	34.0

Change in valuation allowance for tax effect of operating loss carryforwards

	=======	=====	=======	=====
Income tax benefit	\$ (583,890)	(290.0)	\$	
loss carryforwards	(654,073)	(325.0)	(43,565)	(36.0)
orroot or operating				

The net deferred tax asset is comprised of the following:

	February 29, 2004
Allowance for doubtful accounts	\$ 5,000
Accumulated depreciation	20,000
Accumulated amortization	5 <b>,</b> 000
Inventory	125,000
Accrued vacation	6,000
Accrued expenses	31,000
Net operating losses and other carryforwards	1,314,000
Net deferred tax assets before valuation allowance	1,506,000
Deferred tax asset valuation allowance	(921,000)
Net deferred tax asset	\$ 585,000
	========

The change in the valuation allowance was \$794,000 for the year ended February 29, 2004. Of this change, \$585,000 represents the estimated future utilization of approximately \$1,500,000 of the net operating loss carry forward based on the

33

Company's return to profitable operations for the last two fiscal years. \$117,000 of this deferred tax asset has been reflected as a current asset. The \$585,000 has been reflected as a tax benefit in the financial statements.

At February 29, 2004, the Company has available net operating loss carryforwards of approximately \$3,865,000 for income tax purposes, which expire between fiscal 2005 and fiscal 2022. The Company also has research and development credits of approximately \$136,000, which expire between fiscal 2010 and fiscal 2021. The net operating loss and credit carryforwards generated by S&K prior to the acquisition are subject to limitations under Section 382 of the Internal Revenue Code.

#### NOTE 12: STOCK OPTIONS AND WARRANTS

Stock Options - Under the 1993 Stock Incentive Plan, as amended ("1993 Plan"), options can be granted to officers, directors, consultants and employees of the Company and its subsidiaries to purchase up to 1,500,000 of the Company's common shares. Options granted under the 1993 Plan expire on various dates through 2012. The 1993 Plan expired in October 2003 and no further options can be granted under the 1993 Plan. A total of 961,046 options remain outstanding under the 1993 Plan.

Under the 1993 Stock Incentive Plan, option prices were at least 100% of the fair market value of the common stock at time of grant. For qualified employees, except under certain circumstances specified in the 1993 Plan or unless

otherwise specified at the discretion of the Board of Directors, no option may be exercised prior to one year after date of grant, with the balance becoming exercisable in cumulative installments over a three year period during the term of the option, and terminate at a stipulated period of time after an employee's termination of employment.

At the August 21, 2003 Annual Meeting of Shareholders, the Company adopted a new Stock Incentive Plan (the 2003 Plan"). Under this plan, up to 1,500,000 stock options can be granted until 2013. Through February 29, 2004, no options have been granted under this plan.

During Fiscal Year 2004, the Company granted options for 20,000 shares exercisable at \$.19 per share to a director of the Company and options for 10,000 shares at \$.25 to a consultant to the Company. There were no options granted to employees of the Company. During Fiscal Year 2004, compensation expense of \$1,564 was recognized based on the fair value of the options granted to a consultant.

During Fiscal Year 2003, the Company granted options for 415,000 shares exercisable at between \$0.15 per share and \$.30 per share to qualified employees and 40,000 shares exercisable at \$.37 per share to a director of the Company.

34

A summary of the 1993 Plan activity for the years ended February 29, 2004 and February 28, 2003 is as follows:

	Stock Options		Weighted Exercise	Price
	Outstanding	Exercisable	Outstanding	Exercisable
Balance - February 28, 2002	840,062	752 <b>,</b> 187	.50	\$.59
Granted Fiscal Year 2003	445,000		.22	
Canceled Fiscal Year 2003	(162,500)		(.49)	
Balance - February 28, 2003	1,122,562	903,062	\$.33	\$.35
	=======		====	====
Granted Fiscal Year 2004	30,000		.23	
Exercised Fiscal Year 2004	(91,516)		(.16)	
Canceled Fiscal Year 2004	(100,000)		(.52)	
Balance - February 29, 2004	961,046	890,171	\$.32	\$.29
			====	====

Information, at date of issuance, regarding stock option grants for the years ended February 29, 2004 and February 28, 2003:

	Shares	Weighted Average Exercise Price	Weighted Average Fair Value
Year ended February 28, 2003:			
Exercise price exceeds market price	275 <b>,</b> 000	\$ .20	\$ .15
Exercise price equals market price	170,000	.16	.16
Exercise price is less that market price			
Year ended February 29, 2004:			
Exercise price exceeds market price		\$	\$

Exercise price equals market price	30,000	.23	.23
Exercise price is less that market price			

The following table summarizes information about stock options outstanding and exercisable at February 29, 2004:

	Number Outstanding	Weighted- Average Remaining Life in Years 	Weighted Average Exercise Price	Number Exercisable
Range of exercise prices:				
\$ .09 to \$ .20	490,984	8.3	\$.18	461,734
\$ .21 to \$ .50	337,500	4.4	\$.32	280,750
\$ .51 to \$ .90	100,062	4.5	\$.60	100,062
\$1.00 to \$1.53	32,500	6.5	\$1.44	32,500

35

Stock-Based Employee Compensation - The Company accounts for stock-based compensation plans utilizing the provisions of Accounting Principles Board Opinion No. 25 (APB 25), "Accounting for Stock Issued to Employees" and the Financial Accounting Statement of Financial Accounting Standards No. 123 and No. 148 (SFAS 123 and SFAS 148), "Accounting for Stock-Based Compensation". Under SFAS 123, the Company will continue to apply the provisions of APB 25 to its stock-based employee compensation arrangements, and is only required to supplement its financial statements with additional pro-forma disclosures. The Company has elected to provide the related pro-forma disclosures utilizing an intrinsic value method of accounting for such stock based compensation.

The estimated fair value of options granted during Fiscal Year 2004 was \$.23 per share and the estimated fair value of options granted during Fiscal Year 2003 was \$.22 per share. The Company applies Accounting Principles Board Opinion No. 25 and related interpretations in accounting for the 1993 Plan. Had compensation cost for the Company's stock option plan been determined based on the intrinsic value at the option grant dates for awards in accordance with the accounting provisions of SFAS 123, the Company's net income and basic and diluted earnings per share for the years ended February 29, 2004 and February 28, 2003 would have been changed to the pro forma amounts indicated below:

	Year 1	Ended
	February 29, 2004	February 28, 2003
Net income:		
As reported	\$785 <b>,</b> 229	\$120 <b>,</b> 956
Deduct: Total stock based employee compensation under intrinsic value based method for all		
awards, net of tax effects	10,863	101,772
Pro forma net income (loss)	\$774 <b>,</b> 366	\$ 19 <b>,</b> 184
	======	======
Basic earnings per share:		
As reported	\$ 0.08	\$ 0.01

Pro forma	\$ 0.08	\$ 0.00
Diluted earnings per share:		
As reported	\$ 0.07	\$ 0.01
Pro forma	\$ 0.07	\$ 0.00

The fair value of options granted under the Company's fixed stock option plans during Fiscal Years 2004 and 2003 were estimated on the dates of grant using the minimum value options-pricing models with the following weighted-average assumptions used: expected volatility of approximately 109% and 107% in Fiscal Years 2004 and 2003, respectively, risk-free interest rate of approximately 3.25% in Fiscal Years 2004 and 2003, and expected lives of option grants of approximately five years.

36

#### Warrants -

During Fiscal Year 2001, warrants to purchase 50,000 shares of the Company's common stock were issued to a former officer of the Company in acknowledgment of short-term loans granted to the Company in Fiscal Year 2000. One warrant is to purchase 25,000 shares of the Company's common stock at \$0.50 per share, and the other warrant is to purchase 25,000 shares of the Company's common stock at \$1.00 per share. Both warrants expire March 3, 2005.

On February 15, 2000, the Company entered into a 90 day \$100,000 subordinated convertible loan with a non-affiliated individual convertible into common stock at \$1.00 per share. The loan and related interest of 8 % was repaid upon maturity, May 15, 2000. As part of the loan agreement, the lender was eligible to receive a warrant to purchase 50,000 shares of the Company's common stock, if the loan was not converted to equity or was not repaid. When the loan was repaid, the lender received a five-year warrant to purchase 50,000 shares of the Company's common stock at \$1.00 per share in accordance with the provisions of the agreement. The warrant expires on May 15, 2005.

#### NOTE 13: EARNINGS (LOSS) PER SHARE

The following table sets forth the computation of basic and diluted earnings per share:

	February 29, 2004 	February 28, 2003		
Numerator for basic and diluted Earnings per share	\$ 785,229 =======	\$ 120,956 ======		
Denominator:				
Denominator for basic earnings per				
share-weighted average shares	9,096,436	9,152,401		
Effects of dilutive securities:				
Warrants	1,020,085	1,020,085		
Stock options for employees,				
directors and outside consultants	454 <b>,</b> 780	93,158		
December 1. Company of the contract of the con				
Denominator for diluted earnings	11 414 504	10 005 044		
per share	11,414,584			
	========	========		
Basic Earnings Per Share	\$ .08	\$ .01		
-	========	========		

Diluted Earnings Per Share

#### NOTE 14: RELATED PARTY TRANSACTIONS

Norwood loans - On April 30, 2001, in order to induce the advance of an additional \$300,000 by Norwood Venture Corp. ("Norwood"), certain of the Company's directors, an officer and an affiliate of the Company participated in the amount of \$216,750 in the additional mezzanine financing. Interest expense of \$26,571 and \$26,371 was paid to Norwood and forwarded to these individuals during Fiscal Years 2004 and 2003, respectively.

37

Debt Exchange - related party -

During February 2004 loans, accrued interest and prior year consulting fees due to the Chairman of the Company in the amount of \$123,827 were exchanged for 294,825 shares of common stock valued at \$.42 per share. The debt to equity conversion price was negotiated independently with other third party creditors on an "arms length" basis.

Warrant issuance - related party-

During February 2004 warrants to acquire 300,000 shares of the Company's common stock were exercised at \$.30 per share by the Chairman of the Company for \$90,000. The proceeds from this exercise were used to repay prior year loans due to the Chairman.

#### NOTE 15: SIGNIFICANT CUSTOMERS AND FOREIGN SALES

From continuing operations - For the year ended February 29, 2004 one customer accounted for 15% of the Company's sales.

Export sales to customers located outside the United States were approximately as follows:

	February 29, 2004	February 28, 2003
Western Europe	\$552,000	\$356,000
Far East	171,000	170,000
Other	132,000	130,000
	\$855,000	\$656,000
	=======	=======

#### NOTE 15: FOURTH QUARTER ADJUSTMENT (Unaudited)

During the fourth quarter of fiscal 2004, the Company recorded a deferred tax asset of \$585,000 for a portion of the \$3,865,000 of net operating loss carryforwards the Company has available for future utilization due to expire through 2022. See Note 11 - Income Taxes.

#### NOTE 16 - SUBSEQUENT EVENT

On May 13, 2004, the Company and Norwood Venture Corporation modified their Loan Agreement to reschedule repayment terms to commence November 30, 2005 and to end on June 30, 2007. The Note would be repaid in 20 equal installments of \$42,000.

The Put Period in the Agreement was changed to commence with the delivery of the February 29, 2008 audited financial statements. The Agreement was further modified to change the conditions under which the Put Option would terminate to reflect the current stock exchange that the Company's is being traded.

38

#### SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 26, 2004 Sono-Tek Corporation (Registrant)

By: /s/ Dr. Christopher L. Coccio

Dr. Christopher L. Coccio,
Chief Executive Officer and President

KNOW ALL MEN BY THESE PRESENTS, that the undersigned directors and officers of Sono-Tek Corporation, a New York corporation, which is filing its Annual Report on Form 10-KSB with the Securities and Exchange Commission under the provisions of the Securities Exchange Act of 1934, as amended, hereby constitute and appoint Christopher L. Coccio and Duncan Urquhart and each of them their true and lawful attorney-in-fact and agent, with full power and substitution and re-substitution, for him and her and in his or her name, place and stead, in any and all capacities, to sign such Form 10-KSB and any or all amendments to the Form 10-KSB, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all interests and purposes as each of them might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitutes, may lawfully do or cause to be done by virtue hereof.

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

/s/ Dr. Christopher L Coccio	May 26,	2004	/s/ Samuel Schwartz	May	26,	2004
Christopher L. Coccio Chief Executive Officer, President and Director			Samuel Schwartz Chairman and Director			
/s/ Dr. Donald F. Mowbray	May 26,	2004	/s/ Dr. Harvey L Berger	Мау	26,	2004
Donald F. Mowbray Director			Dr. Harvey L. Berger Director			
/s/ R. Stephen Harshbarger	May 26,	2004	/s/ Vincent F. DeMaio	May	26,	2004
R. Stephen Harshbarger Vice President			Vincent F. DeMaio Vice President			